Event submissions
Published
This submission belongs to the session S3. Vaccine Adjuvants of the event The 2nd International Electronic Conference on Vaccines
Published date
25 Nov, 2024
Academic Editor
'%3e%3cpath%20d='M12.6657%2010.9104C12.4185%2010.325%2012.0599%209.79327%2011.6097%209.34482C11.1609%208.89508%2010.6293%208.5365%2010.0442%208.28888C10.0389%208.28626%2010.0337%208.28495%2010.0285%208.28233C10.8446%207.69279%2011.3752%206.73249%2011.3752%205.64904C11.3752%203.8542%209.92103%202.39999%208.1262%202.39999C6.33136%202.39999%204.87715%203.8542%204.87715%205.64904C4.87715%206.73249%205.40774%207.69279%206.22393%208.28364C6.21869%208.28626%206.21345%208.28757%206.20821%208.29019C5.62129%208.5378%205.09463%208.89284%204.64265%209.34613C4.1929%209.79493%203.83432%2010.3266%203.58671%2010.9117C3.34345%2011.4845%203.21226%2012.0987%203.20023%2012.7209C3.19988%2012.7349%203.20233%2012.7488%203.20744%2012.7619C3.21255%2012.7749%203.22022%2012.7867%203.22998%2012.7968C3.23975%2012.8068%203.25142%2012.8147%203.26431%2012.8202C3.2772%2012.8256%203.29105%2012.8284%203.30504%2012.8284H4.09109C4.14874%2012.8284%204.19459%2012.7825%204.1959%2012.7262C4.2221%2011.7148%204.62823%2010.7676%205.34617%2010.0497C6.08899%209.30683%207.0755%208.89808%208.1262%208.89808C9.17689%208.89808%2010.1634%209.30683%2010.9062%2010.0497C11.6242%2010.7676%2012.0303%2011.7148%2012.0565%2012.7262C12.0578%2012.7838%2012.1037%2012.8284%2012.1613%2012.8284H12.9474C12.9613%2012.8284%2012.9752%2012.8256%2012.9881%2012.8202C13.001%2012.8147%2013.0126%2012.8068%2013.0224%2012.7968C13.0322%2012.7867%2013.0398%2012.7749%2013.0449%2012.7619C13.0501%2012.7488%2013.0525%2012.7349%2013.0522%2012.7209C13.0391%2012.0947%2012.9094%2011.4855%2012.6657%2010.9104ZM8.1262%207.9024C7.52486%207.9024%206.9589%207.6679%206.53312%207.24211C6.10733%206.81633%205.87283%206.25037%205.87283%205.64904C5.87283%205.0477%206.10733%204.48174%206.53312%204.05596C6.9589%203.63018%207.52486%203.39567%208.1262%203.39567C8.72753%203.39567%209.29349%203.63018%209.71927%204.05596C10.1451%204.48174%2010.3796%205.0477%2010.3796%205.64904C10.3796%206.25037%2010.1451%206.81633%209.71927%207.24211C9.29349%207.6679%208.72753%207.9024%208.1262%207.9024Z'%20fill='%235D1EE1'/%3e%3c/g%3e%3c/svg%3e)
Srinivasa Reddy BonamCitation
Kishore Alugupalli, Turbo: an adjuvant platform for bacterial glycoconjugate vaccines, in Proceedings of The 2nd International Electronic Conference on Vaccines, 27 November–29 November 2024, MDPI: Basel, Switzerland
Share
Email
FaceBook
Twitter
Linkedin
Turbo: an adjuvant platform for bacterial glycoconjugate vaccines
'%3e%3cpath%20d='M12.6647%2010.9104C12.4176%2010.325%2012.0589%209.7933%2011.6088%209.34485C11.16%208.89511%2010.6283%208.53653%2010.0432%208.28891C10.038%208.28629%2010.0327%208.28498%2010.0275%208.28236C10.8437%207.69282%2011.3743%206.73252%2011.3743%205.64907C11.3743%203.85423%209.92005%202.40002%208.12522%202.40002C6.33038%202.40002%204.87618%203.85423%204.87618%205.64907C4.87618%206.73252%205.40677%207.69282%206.22296%208.28367C6.21772%208.28629%206.21248%208.2876%206.20724%208.29022C5.62031%208.53783%205.09365%208.89287%204.64167%209.34616C4.19192%209.79496%203.83334%2010.3266%203.58573%2010.9117C3.34247%2011.4846%203.21128%2012.0987%203.19925%2012.721C3.1989%2012.735%203.20135%2012.7489%203.20646%2012.7619C3.21157%2012.7749%203.21924%2012.7868%203.22901%2012.7968C3.23877%2012.8068%203.25045%2012.8148%203.26334%2012.8202C3.27623%2012.8256%203.29007%2012.8284%203.30406%2012.8284H4.09012C4.14776%2012.8284%204.19362%2012.7825%204.19493%2012.7262C4.22113%2011.7148%204.62726%2010.7676%205.34519%2010.0497C6.08802%209.30686%207.07452%208.89811%208.12522%208.89811C9.17592%208.89811%2010.1624%209.30686%2010.9052%2010.0497C11.6232%2010.7676%2012.0293%2011.7148%2012.0555%2012.7262C12.0568%2012.7839%2012.1027%2012.8284%2012.1603%2012.8284H12.9464C12.9604%2012.8284%2012.9742%2012.8256%2012.9871%2012.8202C13%2012.8148%2013.0117%2012.8068%2013.0214%2012.7968C13.0312%2012.7868%2013.0389%2012.7749%2013.044%2012.7619C13.0491%2012.7489%2013.0515%2012.735%2013.0512%2012.721C13.0381%2012.0947%2012.9084%2011.4856%2012.6647%2010.9104ZM8.12522%207.90243C7.52388%207.90243%206.95792%207.66793%206.53214%207.24215C6.10636%206.81636%205.87185%206.2504%205.87185%205.64907C5.87185%205.04773%206.10636%204.48177%206.53214%204.05599C6.95792%203.63021%207.52388%203.3957%208.12522%203.3957C8.72655%203.3957%209.29252%203.63021%209.7183%204.05599C10.1441%204.48177%2010.3786%205.04773%2010.3786%205.64907C10.3786%206.2504%2010.1441%206.81636%209.7183%207.24215C9.29252%207.66793%208.72655%207.90243%208.12522%207.90243Z'%20fill='%235D1EE1'/%3e%3c/g%3e%3c/svg%3e)
Kishore Alugupalli 1,2
1. Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.
2. TurboVax Inc, Philadelphia, PA 19104, USA.
Abstract
Keywords
glycoconjugate vaccines
Toll-like receptor
Antibodies
Adjuvant
bacterial infections